Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 1997

View Archived Issues

U.S. Bioscience: Q3 1997 highlights

Sonus: Q3 1997 highlights

Lamisil's safety profile confirmed

39th PDR Annual General Meeting

OXiGENE: Q3 1997 highlights

Spotlight on tryptase inhibitors for asthma

Novel antiangiogenic agent with oral activity in animal model of breast cancer

Mechanism of action and in vivo antitumor efficacy reported for CS-682

Company Profile: Apoptogen

U.S. patent allowed for Hyal's lead product formulations

DAB-720: a new EGF receptor TK inhibitor from Mitsubishi Chemical

Antitumor activity of LC-9018 correlated with cytokine production

Preclinical studies on FK-317 presented at cancer meeting

Endorex raises funds for clinical testing of antitumor drugs

New MRI contrast agent available in Europe

NIH awards Vaxcel two grants for vaccine research

Oxford BioMedica acquires novel anticancer technology

Effexor XR cleared by FDA

Ferrer to distribute Orthovisc in Spain, Portugal

Sibia's TBA technology licensed to Neurocrine Biosciences

Structure of NO-producing enzyme solved

Shaman issued U.S. patent for antidiabetic compounds

VZIG study in postherpetic neuralgia stopped; chickenpox study continues

Cangene to manufacture new formulation of NABI's H-BIG

Alexion reports phase I/II and IIa results for C5 inhibitor

Research team identifies effector of morphological changes during apoptosis

Dyax and Tularik establish drug discovery collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...